Schedule 13G ownership disclosure

MILESTONE PHARMACEUTICALS IN

Common Stock · CUSIP: 59935V107

Event date: 2025-07-11

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Propel Bio Management, LLC

    Shares: 8,861,186.00 · Class: 9.9%

  • Leen Kawas

    Shares: 8,861,186.00 · Class: 9.9%

  • Richard Kayne

    Shares: 8,861,186.00 · Class: 9.9%

  • Propel Bio Partners LLC

    Shares: 8,861,186.00 · Class: 9.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001969764-25-000003
Form type
SCHEDULE 13G
Filer
Milestone Pharmaceuticals Inc.
CIK
CIK 1408443
Filed
Dec 23, 2025
Reporting period
Jul 11, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub